Topical corticosteroids

Mild-to-Moderate Psoriasis, Second Edition

Volumn , Issue , 2008, Pages 23-39

  Givan, Jason ^a   Pearce, Daniel ^b   Feldman, Steven R ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123128116     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (63)

1. Pearce DJ, Stealey KH, Balkrishnan R, et al. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol 2006; 45(4):370-374.
2. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14(3):485-496.
3. Kragballe K. Topical corticosteroids: Mechanisms of action. Acta Derm Venereol Suppl (Stockh) 1989; 151:7-10.
4. Van De Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 2003; 16(2):69-83.
5. Murray JR. The history of corticosteroids. Acta Derm Venereol Suppl (Stockh) 1989; 151:4-6.
6. Fritz KA, Weston WL. Topical glucocorticosteroids. Ann Allergy 1983; 50(2):68-76.
7. Lee SS. Topical steroids. Int J Dermatol 1981; 20(10):632-641.
8. Katz M, Shaikh ZI. Percutaneous corticosteroid absorption correlated to partition coefficient. J Pharm Sci 1965; 54(4):591-594.
9. Hepburn DJ, Aeling JL, Weston WL. A reappraisal of topical steroid potency. Pediatr Dermatol 1996; 13(3):239-245.
10. Mckenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962; 86:608-610.
11. Gao HY, Li Wan PA. Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity? Eur J Clin Pharmacol 1994; 46(1):71-75.
12. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006; 55(4):607-613.
13. Feldman S, Housman T. Patients' vehicle preference for corticosteroid treatments of psoriasis. Am J Clin Dermatol 2003; 4(4):221-224.
14. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: Are ointments really more potent? J Drugs Dermatol 2006; 5(6):527-532.
15. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol 2004; 51(2):212-216.
16. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57(1): 81-83.
17. Miller JJ, Roling D, Margolis D, et al. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol 1999; 41(4):546-549.
18. Smith K. Skin Cap: What have we learned, and when did we learn it? [Editorial]. Dermatol Online J 1997; 3(2):11c.
19. Shelley WB, Shelley ED. A dermatologic diary. Portrait of a practice. Cutis 1997; 59(4):181-182.
20. Housman TS, Keil KA, Mellen BG, et al. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol 2003; 49(1):79-82.
21. Goldberg B, Hartdegen R, Presbury D, et al. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991; 25 (6, pt 2):1145-1148.
22. Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobe-tasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991; 25 (6 Pt 2):1153-1156.
23. Katz HI, Gross E, Buxman M, et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol 1991; 25(6, pt 2):1175-1178.
24. Gottleib AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003; 7:185-192.
25. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142(5):931-936.
26. Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A Review. Drugs 1988; 36(suppl 5):51-61.
27. Jones EW. Steroid atrophy-A histological appraisal. Dermatologica 1976; 152 (suppl 1):107-115.
28. Kerscher MJ, Hart H, Korting HC, et al. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 1995; 33(4):187-189.
29. Kerscher MJ, Korting HC. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis. Skin Pharmacol 1992; 5(2):77-80.
30. Kerscher MJ, Korting HC. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound. Acta Derm Venereol 1992; 72(3):214-216.
31. Korting HC, Vieluf D, Kerscher M. 0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 1992; 42(2):159-161.
32. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: Clinical implications. Am J Clin Dermatol 2002; 3(3):141-147.
33. Nathan AW, Rose GL. Fatal iatrogenic cushing's syndrome. Lancet 1979; 1(8109):207.
34. Kubo T, Kojima A, Yamazoe S, et al. Osteonecrosis of the femoral head that developed after long-term topical steroid application. J Orthop Sci 2001; 6(1):92-94.
35. Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris-Clinical efficacy and adrenal function. J Am Acad Dermatol 1987; 16: 804-811.
36. Munro DD. The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in in-patients. Br J Dermatol 1976; 94(suppl 12): 67-76.
37. Crespi HG. Topical corticosteroid therapy for children: Alclometasone dipropionate cream 0.05%. Clin Ther 1986; 8(2):203-210.
38. Lucky AW, Grote GD, Williams JL, et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 1997; 59(3):151-153.
39. Rasmussen JE. Percutaneous absorption of topically applied triamcinolone in children. Arch Dermatol 1978; 114(8):1165-1167.
40. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999; 140(6):1114-1121.
41. Vernon HJ, Lane AT, Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991; 24(4):603-607.
42. Weston WL, Sams WM Jr, Morris HG, et al. Morning plasma cortisol levels in infants treated with topical fluorinated glucocorticosteroids. Pediatrics 1980; 65(1): 103-106.
43. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984; 1(3):246-253.
44. Juhlin L. Comparison of fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, in the treatment of eczema. Cutis 1996; 57(2)(suppl):51-56.
45. Kelly JW, Cains GD, Rallings M, et al. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses. Australas J Dermatol 1991; 32(2):85-91.
46. Bhardwaj SS, Camacho F, Derrow A, et al. Statistical significance and clinical relevance: The importance of power in clinical trials in dermatology. Arch Dermatol 2004; 140(12):1520-1523.
47. Korting HC, Unholzer A, Schafer-Korting M, et al. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002; 15(2):85-91.
48. Schafer-Korting M, Korting HC, Kerscher MJ, et al. Prednicarbate activity and benefit/ risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 1993; 54(4):448-456.
49. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46(6):850-860.
50. Pearce DJ, Thomas CG, Fleischer AB Jr, et al. The cost of psoriasis therapies: Considerations for therapy selection. Dermatol Nurs 2004; 16(5):421-428, 432.
51. Kulkarni AS, Balkrishnan R, Richmond D, et al. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J Am Acad Dermatol 2005; 52(1):27-31.
52. Farmer KC, Jacobs EW, Phillips CR. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin Ther 1994; 16(2):316-326.
53. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990; 150(7):1509-1510.
54. Wannamaker BB, Morton WA Jr, Gross AJ, et al. Improvement in antiepileptic drug levels following reduction of intervals between clinic visits. Epilepsia 1980; 21(2): 155-162.
55. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150(7):1377-1378.
56. Feldman SR, Fleischer AB, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: Dermatologists remain the primary providers of this care. Int J Dermatol 2000; 39(1):41-44.
57. Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: A Multicentre, Double-Blind, Randomized Study. Br J Dermatol 1998; 138(2):254-258.
58. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996; 35(2, pt 1):268-269.
59. Lebwohl M, Yoles A, Lombardi K, et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: Effects on the duration of improvement. J Am Acad Dermatol 1998; 39:447-450.
60. Carroll CL, Clarke J, Camacho F, et al. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005; 141(1):43-46.
61. Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48(4): 564-568.
62. Feldman SR. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: Add-on therapy in the cobra trial. Cutis 2007; 80(5)(suppl):20-28.
63. Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the cobra trial. Cutis 2007; 80(5)(suppl):12-19.